Sculptor Capital’s Ocular Therapeutix OCUL Stock Holding History

Sculptor Capital’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-42,800	Closed	-$130K	–	310
2019 Q3	$130K	Hold	42,800	–	–	﹤0.01%	284
2019 Q2	$188K	Buy	+42,800	New	+$158K	﹤0.01%	264
2017 Q4	–	Sell	-49,600	Closed	-$307K	–	117
2017 Q3	$307K	Buy	49,600 +38,900	+364%	+$250K	﹤0.01%	312
2017 Q2	$99K	Buy	+10,700	New	+$104K	﹤0.01%	310

Other funds holding OCUL

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

DAM

Deltec Asset Management New York $545M AUM 33.4% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SHI

SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sculptor Capital's OCUL Position: Q4 2019 in Review

Sculptor Capital sold out of Ocular Therapeutix (OCUL) in Q4 2019, closing a stake of 42,800 shares — an estimated $130K sold.

Sculptor Capital first reported a position in OCUL in Q2 2017 and held it in 4 quarters. The position peaked at $307K in Q3 2017. 79 funds tracked by Wall St. Rank hold OCUL as of Q4 2019.

Sculptor Capital reported no remaining Ocular Therapeutix position as of Q4 2019 after selling out during the quarter.
Sculptor Capital sold 42,800 Ocular Therapeutix shares in Q4 2019, an estimated $130K.
Sculptor Capital first reported a position in Ocular Therapeutix in Q2 2017 and held it in 4 quarters.
Sculptor Capital's Ocular Therapeutix position peaked at $307K in Q3 2017.
79 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q4 2019.

Based on Sculptor Capital's 13F filing for Q4 2019, filed 14 Feb 2020.